Combination therapy in peripheral vascular disease: the rationale of using both thrombolytic and antiplatelet drugs. (Q34500263)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11800349%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Combination therapy in peripheral vascular disease: the rationale of using both thrombolytic and antiplatelet drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11800349%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

1 reference

Richard D Shlansky-Goldberg

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11800349%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

Richard Shlansky-Goldberg

series ordinal

1

1 reference

2 August 2017

publication date

1 January 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11800349%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American College of Surgeons

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11800349%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

194

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11800349%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

1 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11800349%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

S103-13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11800349%20AND%20SRC:MED&resulttype=core&format=json

Pulsed-spray pharmacomechanical thrombolysis: preliminary clinical results

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Acceleration of thrombolysis with a high-dose transthrombus bolus technique.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Intraarterial thrombolysis of lower extremity occlusions: prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Multilevel Infusion Catheter for Use with Thrombolytic Agents

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Urokinase thrombolysis using a multiple side hole multilumen infusion catheter

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Symptomatic native arterial occlusions: early experience with "over-the-wire" thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

THROMBASTHENIA. STUDIES ON THREE CASES

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

An Abnormal Platelet Glycoprotein Pattern in Three Cases of Glanzmann's Thrombasthenia

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Thrombosis and the role of the platelet

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Recognition of the importance of embolization in atherosclerotic vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

1 reference

7 January 2021

Clinical pharmacology of eptifibatide

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Platelets and thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation?

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

The adjuvant use of the monoclonal antibody c7E3 Fab in peripheral arterial thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901098-5

7 January 2021

10.1016/S1072-7515(01)01098-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11800349%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference